- Home
- CWD vs RDHL Comparison
CWD vs RDHL Comparison
Compare CWD & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWD
- RDHL
- Stock Information
- Founded
- CWD 2009
- RDHL 2009
- Country
- CWD United States
- RDHL Israel
- Employees
- CWD N/A
- RDHL N/A
- Industry
- CWD Real Estate
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- CWD Finance
- RDHL Health Care
- Exchange
- CWD Nasdaq
- RDHL Nasdaq
- Market Cap
- CWD 4.5M
- RDHL 3.9M
- IPO Year
- CWD 2023
- RDHL N/A
- Fundamental
- Price
- CWD $2.74
- RDHL $1.48
- Analyst Decision
- CWD
- RDHL
- Analyst Count
- CWD 0
- RDHL 0
- Target Price
- CWD N/A
- RDHL N/A
- AVG Volume (30 Days)
- CWD 43.0K
- RDHL 1.4M
- Earning Date
- CWD 08-11-2025
- RDHL 08-28-2025
- Dividend Yield
- CWD N/A
- RDHL N/A
- EPS Growth
- CWD N/A
- RDHL N/A
- EPS
- CWD N/A
- RDHL N/A
- Revenue
- CWD $35,429,000.00
- RDHL $8,042,999.00
- Revenue This Year
- CWD N/A
- RDHL $381.91
- Revenue Next Year
- CWD $31.12
- RDHL N/A
- P/E Ratio
- CWD N/A
- RDHL N/A
- Revenue Growth
- CWD N/A
- RDHL 23.17
- 52 Week Low
- CWD $2.33
- RDHL $1.43
- 52 Week High
- CWD $15.80
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- CWD 40.85
- RDHL 37.66
- Support Level
- CWD $2.33
- RDHL $1.86
- Resistance Level
- CWD $2.98
- RDHL $3.31
- Average True Range (ATR)
- CWD 0.31
- RDHL 0.31
- MACD
- CWD 0.00
- RDHL -0.08
- Stochastic Oscillator
- CWD 31.85
- RDHL 2.39
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.